We have found that systemic dosing of an anti-TfR antibody–PMO conjugate can access the central compartment and affect the splicing of the SMN2 mRNA to levels previously observed only with direct cerebral or intrathecal drug administration, rescuing survival in severe SMA mice. Here, SMN2 is linked to proximal spinal muscular atrophy.